Quince Therapeutics, Inc. — Form 8-K
Filed August 14, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 75/100
What the filing says
Quince completed a stock-for-stock merger with Orphai Therapeutics on May 18, 2026, acquiring LAM-001 (inhaled rapamycin) for PH-ILD, BOS, and SAPH. Concurrent private placement raised $115M gross ($103.6M net), with potential $83M additional from warrant exercise. Cash position is $116M as of June 30, 2026, expected to fund operations through end of 2028. Q2 2026 net loss was $75.5M ($12.31/share on 978,022 shares); LAM-001 Phase 2b PH-ILD data expected Q1 2028, Phase 2 BOS data expected Q1 2027.
Why this rating
Transformational M&A with late-stage pipeline asset and substantial capital raise (180% of prior market cap), significantly extending runway and pivoting strategy. Meaningful near-term positive catalyst.
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.